CompanyGraph
Shanghai International Medical Instruments Co., Ltd.
1501 · HKEX · China
int-medical.comFinancials as of FY2025
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
At a glance
- Depends onUpstream position: supplies 5 industries, depends on 1
- ScaleLevered free cash flow is $29.02M, above the global median of $16.24M
- FinancialsAltman Z-Score 3.64: safe zone
- Interpretations5 currently firing — 5
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.78%Below 5Y avg (1.10%)
Annual Rate
HKD 0.26Paid unknown
Payout Ratio
0.0%Sustainable
Last Ex-Dividend
Jun 3, 2026
The reported statements, read against the company's own industry.
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
Financials view
Market Capitalization
5.23BHKD667.12M · vs all stocks (USD)
Trailing P/E
22.22xvs Medical Instruments & Supplies peers
Revenue (TTM)
1.24BCNY158.09M · vs all stocks (USD)
Profit Margin
20.53%vs Medical Instruments & Supplies peers
Beta
0.0800xvs all stocks
52-Week Change
-2.67%vs all stocks
Forward Annual Dividend Yield
0.78%vs all stocks
Market Capitalization
5.23BHKD667.12M · vs all stocks (USD)
Enterprise Value
8.33BHKD1.06B · vs all stocks (USD)
Trailing P/E
22.22xvs Medical Instruments & Supplies peers
Forward P/E
20.76xvs Medical Instruments & Supplies peers
Price to Sales (TTM)
6.42xvs Medical Instruments & Supplies peers
Price to Book (MRQ)
2.45xvs Medical Instruments & Supplies peers
Enterprise to Revenue
6.71xvs Medical Instruments & Supplies peers
Enterprise to EBITDA
20.26xvs Medical Instruments & Supplies peers
Profit Margin
20.53%vs Medical Instruments & Supplies peers
Operating Margin
23.31%vs Medical Instruments & Supplies peers
Return on Assets (TTM)
5.99%vs Medical Instruments & Supplies peers
Return on Equity (TTM)
12.01%vs Medical Instruments & Supplies peers
Revenue (TTM)
1.24BCNY158.09M · vs all stocks (USD)
Revenue per Share (TTM)
6.49CNYUpdated Aug 19, 2026Quarterly Revenue Growth
31.50%vs Medical Instruments & Supplies peers
Gross Profit (TTM)
741.08MCNY94.48M · vs all stocks (USD)
EBITDA (TTM)
367.94MCNY46.91M · vs all stocks (USD)
Net Income (TTM)
240.01MCNY30.60M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
31.60%vs Medical Instruments & Supplies peers
Operating Cash Flow (TTM)
405.12MCNY51.65M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
227.63MCNY29.02M · vs all stocks (USD)
Forward Annual Dividend Rate
0.2600HKDUpdated Aug 19, 2026Forward Annual Dividend Yield
0.78%vs all stocks
Trailing Annual Dividend Rate
0.2300HKDUpdated Aug 19, 2026Trailing Annual Dividend Yield
0.69%vs all stocks
5-Year Average Dividend Yield
1.10%vs all stocks
Payout Ratio
0.00%vs Medical Instruments & Supplies peers
Minority Interest (Equity)
92.88MCNYFY2025 · Dec 31, 2025Revenue
1.07BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
428.69MCNYFY2025 · Dec 31, 2025Gross Profit
636.79MCNYFY2025 · Dec 31, 2025Operating Income
258.69MCNY38.36M · vs all stocks (USD)
Pre-tax Income
258.32MCNYFY2025 · Dec 31, 2025Income Tax Expense
25.65MCNYFY2025 · Dec 31, 2025Net Income
232.67MCNYFY2025 · Dec 31, 2025EBIT
270.87MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
367.94MCNYFY2025 · Dec 31, 2025Research & Development
150.06MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
266.05MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
11.99MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
12.54MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-13.89MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
12.56MCNYFY2025 · Dec 31, 2025Operating Cash Flow
288.78MCNYFY2025 · Dec 31, 2025Free Cash Flow
225.83MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
630.71MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
258.32MCNYFY2025 · Dec 31, 2025Stock-based Compensation
8.07MCNYFY2025 · Dec 31, 2025Other Non-cash Items
554.00KCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
12.97MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
8.86MCNYFY2025 · Dec 31, 2025Capital Expenditures
-62.95MCNYFY2025 · Dec 31, 2025Net Intangibles (CF)
-50.13MCNYFY2025 · Dec 31, 2025Net Acquisitions
-300.18MCNYFY2025 · Dec 31, 2025Purchase of Investments
-469.31MCNYFY2025 · Dec 31, 2025Sale of Investments
336.60MCNYFY2025 · Dec 31, 2025Other Investing Activity
-18.31MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-514.15MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-447.25MCNYFY2025 · Dec 31, 2025Net Short-term Debt Issuance
291.54MCNYFY2025 · Dec 31, 2025Other Financing Charges
57.72MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-101.59MCNYFY2025 · Dec 31, 2025Shares Outstanding
174.25MSharesUpdated Aug 19, 2026Float Shares
86.30MSharesUpdated Aug 19, 2026% Held by Insiders
71.67%vs all stocks
% Held by Institutions
13.20%vs all stocks
Total Cash (MRQ)
757.40MCNY96.56M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.11CNYUpdated Aug 19, 2026Total Debt (MRQ)
833.21MCNY106.23M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.3429xvs Medical Instruments & Supplies peers
Current Ratio (MRQ)
1.26xvs Medical Instruments & Supplies peers
Book Value per Share (MRQ)
13.33CNYUpdated Aug 19, 2026Total Assets
3.13BCNY464.47M · vs all stocks (USD)
Total Current Assets
1.02BCNYFY2025 · Dec 31, 2025Total Liabilities
1.04BCNYFY2025 · Dec 31, 2025Total Non-current Assets
2.11BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
233.22MCNYFY2025 · Dec 31, 2025Total Current Liabilities
810.55MCNYFY2025 · Dec 31, 2025Cash
610.71MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
610.71MCNYFY2025 · Dec 31, 2025Other Short-term Investments
20.11MCNYFY2025 · Dec 31, 2025Accounts Receivable
105.75MCNYFY2025 · Dec 31, 2025Inventory
195.00MCNYFY2025 · Dec 31, 2025Accounts Payable
63.26MCNYFY2025 · Dec 31, 2025Short-term Debt
528.09MCNYFY2025 · Dec 31, 2025Long-term Debt
187.87MCNYFY2025 · Dec 31, 2025Common Stock (Book)
176.00MCNYFY2025 · Dec 31, 2025Retained Earnings
782.88MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.09BCNY309.68M · vs all stocks (USD)
Treasury Stock
43.79MCNYFY2025 · Dec 31, 202552-Week Low
27.86HKDUpdated Aug 19, 202652-Week High
41.40HKDUpdated Aug 19, 202652-Week Change
-2.67%vs all stocks
Beta
0.0800xvs all stocks
50-Day MA
31.97HKDUpdated Aug 19, 2026200-Day MA
32.32HKDUpdated Aug 19, 2026Avg 10-Day Volume
284.42KSharesUpdated Aug 19, 2026Avg 30-Day Volume
276.85KSharesUpdated Aug 19, 2026Diluted EPS (TTM)
1.47CNYUpdated Aug 19, 20265 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Revenue is growing, but receivables have grown faster over the last six to eight yearsSignificant
Revenue Growth YoY: 0.32Receivables vs revenue divergence: 3.47
Financial Health
Altman Z-Score 3.64: safe zoneNotable
Altman Z-Score: 3.64
Supply Chain
Upstream position: supplies 5 industries, depends on 1Notable
Outgoing: 5.00Incoming: 1.00
Scale
Levered free cash flow is $29.02M, above the global median of $16.24MNotable
Levered free cash flow (USD): 29,020,898.278Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Suzhou Sunmun Technology Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionSenseMakingRule
Hochiki Corporation
Tier 1ProductionThroughput-Bound ConversionRuleFlow
Chimin Health Management Inc.
Tier 1ProductionThroughput-Bound ConversionRule
Sunflag Iron & Steel Co. Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Zhang Xiaoquan Inc.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Pentamaster Corporation Berhad
Tier 1ProductionThroughput-Bound ConversionSenseMakingRule
Marssenger Kitchenware Co. Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Suzhou Wanxiang Technology Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Zhejiang Kaier New Materials Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionRuleFlow
Henan Tong-Da Cable Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Suzhou Sepax Technologies Inc.
5 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash-Flow Ratios ElevatedOperating Income Growing With Multi-Year Revenue GrowthMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin Elevated
Moshi Moshi Retail Corp PLC
5 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash-Flow Ratios ElevatedOperating Income Growing With Multi-Year Revenue GrowthMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin Elevated
Global Ship Lease Inc.
5 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash-Flow Ratios ElevatedOperating Income Growing With Multi-Year Revenue GrowthMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin Elevated